Analysis of CEP55 pan cancer immune and prognostic based on TCGA and GTEx databases

Article ID: 4739

Abstract

Overview

Background

The CEP55 encoded product is a centrosome protein.Participate in the development of the cranioskeletal system，Establish protein localizationand intermediate separation。Acting on the upstream or internal division of mitotic cells。CEP55 can affect the prognosis of various tumor types through multiple pathways。We evaluated the role of CEP55 using pan cancer data from the Cancer Genome Atlas (TCGA) and Genotyping Tissue Expression (GTEx) projects.

Method

The potential role of CEP55 in different tumors was explored based on the Cancer Genome Atlas (TCGA) and Genotyping Tissue Expression (GTEx) datasets.CEP55 related expression differences, tumor mutation burden (TMB), microsatellite instability (MSI), MATH, clinical staging and gene expression, immune cell analysis (xCELL, CIBERSORT, Timer), gene expression prognosis, etc.Our research findings indicate that CEP55 affects the prognosis of cancer patients, and its role varies among different types of cancer。In some cases, elevated CEP55 gene expression is detrimental to survival, while the opposite is true in other tumor types.

 Result

CEP55 在各种肿瘤组织和癌症邻近的正常组织中表达存在差异。CEP55 与 TMB 和 MIS 等常见免疫治疗靶点相关，开发与 CEP55 相关的药物，具有通过 TMB 和 MSI 免疫靶点治疗相关肿瘤的潜力。CEP55 与肿瘤的临床分期相关，可作为临床肿瘤不同阶段调整治疗方案的依据。CEP55 在各种免疫细胞分析中显示出显著的相关性，表明 CEP55 广泛影响肿瘤免疫细胞，进而可能影响各种肿瘤的免疫调节，并可能参与多种肿瘤免疫微环境的调节，有可能作为潜在的免疫治疗靶点。CEP55 可能是一个潜在的新治疗靶点。

结论

CEP55 的表达在不同肿瘤之间有所不同，并且与各种肿瘤的临床分期相关。它可能参与多种肿瘤的免疫调节，并可能作为潜在的治疗靶点。